AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22157067 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall decision making effect of MRI
Number of subjects: 0
Study 19758580 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle weight loss intervention (LW)
Number of subjects: 300
Study 19758580 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (UC)
Number of subjects: 300
Study 18190829 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous bladder irrigation
Number of subjects: 80
Study 18190829 — intervention group
Group type: COMPARATOR
Intervention: No bladder irrigation (control)
Number of subjects: 80
Study 16183781 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiverine 15 mg twice daily for 7 days
Number of subjects: 16
Study 16183781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12817154 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 1088
Study 12817154 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 1088
Study 11291023 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychopharmacologic treatment for hypersexuality
Number of subjects: 0
Study 11291023 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical algorithm for treatment
Number of subjects: 0
Study 8704114 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flux biocompatible membrane
Number of subjects: 159
Study 8704114 — intervention group
Group type: COMPARATOR
Intervention: Low-flux bioincompatible membrane
Number of subjects: 159
Study 31711417 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 20 mg (E group)
Number of subjects: 70
Study 31711417 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 250 mcg (P group)
Number of subjects: 70
Study 31711417 — intervention group
Group type: COMPARATOR
Intervention: Saline (C group)
Number of subjects: 70
Study 29463484 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive nursing skills mobile application
Number of subjects: 66
Study 29463484 — intervention group
Group type: COMPARATOR
Intervention: Noninteractive nursing video contents
Number of subjects: 66
Study 26606274 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of Motor and Process Skills (AMPS) motor scale
Number of subjects: 30
Study 26606274 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of Motor and Process Skills (AMPS) process scale
Number of subjects: 30
Study 26606274 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-rater reliability for AMPS motor scale
Number of subjects: 30
Study 26606274 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-rater reliability for AMPS process scale
Number of subjects: 30
Study 23801545 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 143
Study 22154131 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention consisting of 4 tailored newsletters and 2 motivational phone calls
Number of subjects: 43
Study 22154131 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving 4 children's books
Number of subjects: 43
Study 18721085 — intervention group
Group type: EXPERIMENTAL
Intervention: Free and Easy Wanderer Plus (FEWP)
Number of subjects: 150
Study 18721085 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 150
Study 18721085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 16648333 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-feedback interactional treatment
Number of subjects: 80
Study 16648333 — intervention group
Group type: COMPARATOR
Intervention: Supportive counseling (Control)
Number of subjects: 80
Study 12732774 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction (Jackson-Pratt) drains
Number of subjects: 164
Study 12732774 — intervention group
Group type: COMPARATOR
Intervention: No drains
Number of subjects: 164
Study 10926346 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate combination product (SFC) 50/250 microg twice daily
Number of subjects: 0
Study 10926346 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 800 microg twice daily
Number of subjects: 0
Study 9187592 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-triggered pressure-support ventilation at 75% ventilatory support
Number of subjects: 16
Study 9187592 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-triggered pressure-support ventilation at 75% ventilatory support
Number of subjects: 16
Study 1526015 — intervention group
Group type: COMPARATOR
Intervention: Phosphoramidon (control)
Number of subjects: 41
Study 1526015 — intervention group
Group type: EXPERIMENTAL
Intervention: UK 79300 (100 mg, twice daily)
Number of subjects: 41
Study 1526015 — intervention group
Group type: EXPERIMENTAL
Intervention: UK 79300 (25 mg)
Number of subjects: 41
Study 1526015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 2868640 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg tablet of Ea-0643 (group-A)
Number of subjects: 56
Study 2868640 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg tablet of Ea-0643 (group-B)
Number of subjects: 56
Study 2868640 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet (group-C)
Number of subjects: 56
Study 29193471 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative assessment-based nursing intervention
Number of subjects: 184
Study 29193471 — intervention group
Group type: COMPARATOR
Intervention: Regular nursing (control group)
Number of subjects: 184
Study 27978537 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd63 ME-TRAP followed by MVA ME-TRAP (prime-boost vaccination)
Number of subjects: 120
Study 27978537 — intervention group
Group type: COMPARATOR
Intervention: Anti-rabies vaccine (control group)
Number of subjects: 120
Study 23962321 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS combined with CIMT
Number of subjects: 19
Study 23962321 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS combined with CIMT
Number of subjects: 19
Study 22976514 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy applied with output power of 100 mW in continuous mode with sweeping motion.
Number of subjects: 100
Study 22976514 — intervention group
Group type: COMPARATOR
Intervention: Control group with no laser energy applied (only brought into position).
Number of subjects: 100
Study 21044723 — intervention group
Group type: COMPARATOR
Intervention: Wheelchair tilt-in-space at 35° with 100° recline
Number of subjects: 11
Study 21044723 — intervention group
Group type: COMPARATOR
Intervention: Wheelchair tilt-in-space at 15°, 25°, and 35° with 120° recline
Number of subjects: 11
Study 21044723 — intervention group
Group type: COMPARATOR
Intervention: Wheelchair tilt-in-space at 15° and 25°
Number of subjects: 11
Study 18607726 — intervention group
Group type: EXPERIMENTAL
Intervention: Community and school-based anti-violence media intervention ('Resolve It, Solve It')
Number of subjects: 0
Study 18607726 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 16644631 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg muraglitazar
Number of subjects: 1159
Study 16644631 — intervention group
Group type: COMPARATOR
Intervention: 30 mg pioglitazone
Number of subjects: 1159
Study 14585016 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase shifts of feedback
Number of subjects: 0
Study 14585016 — intervention group
Group type: EXPERIMENTAL
Intervention: Period shifts of pitch contents for synchronized feedback
Number of subjects: 0
Study 14585016 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined phase and period shifts
Number of subjects: 0
Study 14585016 — intervention group
Group type: EXPERIMENTAL
Intervention: All feedback conditions in the same session
Number of subjects: 0
Study 10657761 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin (CAP) 0.05% liniment applied 3 times daily for 5 days
Number of subjects: 10
Study 10657761 — intervention group
Group type: COMPARATOR
Intervention: Placebo substance (vehicle)
Number of subjects: 10
Study 10657761 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin (CAP)
Number of subjects: 10
Study 8928705 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 300 U/kg
Number of subjects: 200
Study 8928705 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 100 U/kg
Number of subjects: 200
Study 8928705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 1510019 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided breathing retraining
Number of subjects: 41
Study 1510019 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided breathing retraining with physiologic monitoring of thoracic and abdominal movement plus peripheral temperature
Number of subjects: 41
Study 1510019 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided breathing retraining with physiologic monitoring of thoracic and abdominal movement, peripheral temperature and end‐tidal carbon dioxide
Number of subjects: 41
Study 1510019 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 41
Study 6208603 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral prostatectomy (TURP)
Number of subjects: 75
Study 6208603 — intervention group
Group type: COMPARATOR
Intervention: Transvesical prostatectomy (TVP)
Number of subjects: 75
Study 31100050 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Lactobacillus rhamnosus GG (Culturelle, 20 billion live organisms) instillation
Number of subjects: 10
Study 31032742 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment (MicroLaserPeel™ and ProFractional™)
Number of subjects: 19
Study 31032742 — intervention group
Group type: COMPARATOR
Intervention: Control side (untreated)
Number of subjects: 19
Study 30481882 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg‐IFN alfa‐2a for 48 weeks
Number of subjects: 303
Study 30481882 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg‐IFN alfa‐2a for 96 weeks
Number of subjects: 303
Study 30481882 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg‐IFN alfa‐2a for 48 weeks and 96 weeks
Number of subjects: 303
Study 27316780 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention promoting fruit and vegetable consumption (F/V) via a videogame
Number of subjects: 400
Study 24684829 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 119
Study 22426952 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning teriparatide (20 μg daily)
Number of subjects: 50
Study 22426952 — intervention group
Group type: COMPARATOR
Intervention: Evening teriparatide (20 μg daily)
Number of subjects: 50
Study 20722561 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg/day) for 3 months
Number of subjects: 40
Study 20722561 — intervention group
Group type: COMPARATOR
Intervention: Stable dose of ACEIs and/or ARBs
Number of subjects: 40
Study 18755192 — intervention group
Group type: EXPERIMENTAL
Intervention: High salivary testosterone levels
Number of subjects: 0
Study 18755192 — intervention group
Group type: COMPARATOR
Intervention: Low salivary testosterone levels
Number of subjects: 0
Study 15864242 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 71
Study 15864242 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 71
Study 12755652 — intervention group
Group type: EXPERIMENTAL
Intervention: History of suicide attempts
Number of subjects: 648
Study 12755652 — intervention group
Group type: EXPERIMENTAL
Intervention: History of sexual abuse, lack of confidant prior to illness onset, more prior hospitalizations for depression, suicidal thoughts when depressed, and cluster B personality disorder
Number of subjects: 648
Study 10773129 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hernioplasty (TAPP)
Number of subjects: 176
Study 8633952 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-mm HP St. Jude Medical valve
Number of subjects: 66
Study 8633952 — intervention group
Group type: COMPARATOR
Intervention: 21-mm standard valve
Number of subjects: 66
Study 8633952 — intervention group
Group type: COMPARATOR
Intervention: 23-mm standard valve
Number of subjects: 66
Study 1333741 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine-aspirin
Number of subjects: 12
Study 1333741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3001610 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir
Number of subjects: 55
Study 30573499 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical brimonidine tartrate 0.15% administered 20 min prior to injection
Number of subjects: 58
Study 30573499 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 58
Study 30695661 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib and Trastuzumab
Number of subjects: 0
Study 30695661 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29136445 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 μg peanut patch
Number of subjects: 221
Study 29136445 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 221
Study 29136445 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg peanut patch
Number of subjects: 221
Study 29136445 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 μg peanut patch
Number of subjects: 221
Study 29136445 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 μg peanut patch (6-11 years)
Number of subjects: 221
Study 29136445 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 μg peanut patch (adolescents/adults)
Number of subjects: 221
Study 29136445 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (TEAEs)
Number of subjects: 221
Study 25935227 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracardiac echocardiography (ICE)
Number of subjects: 122
Study 25935227 — intervention group
Group type: COMPARATOR
Intervention: Transesophageal echocardiogram (TEE)
Number of subjects: 122
Study 23855376 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based guided stress-management training based on problem solving and emotion regulation.
Number of subjects: 264
Study 23855376 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group for six months.
Number of subjects: 264
Study 23855376 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based guided stress-management training.
Number of subjects: 264
Study 23855376 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis from a societal perspective.
Number of subjects: 264
Study 21737951 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 63
Study 21737951 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin
Number of subjects: 63
Study 19362316 — intervention group
Group type: EXPERIMENTAL
Intervention: QTinno
Number of subjects: 1422
Study 19362316 — intervention group
Group type: COMPARATOR
Intervention: Global
Number of subjects: 1422
Study 19362316 — intervention group
Group type: COMPARATOR
Intervention: Tangent
Number of subjects: 1422
Study 16300723 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance group (listened to a rationale for accepting emotions)
Number of subjects: 60
Study 16300723 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression group (listened to a rationale for suppressing emotions)
Number of subjects: 60
Study 16300723 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance group
Number of subjects: 60
Study 16300723 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 60
Study 15027519 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactic acid 12% and pramoxine hydrochloride 1% cream applied twice daily for 7 days
Number of subjects: 24
Study 11309549 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotrafiban (5-100 mg, twice daily for 12 weeks)
Number of subjects: 0
Study 11309549 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotrafiban (exposure > 835 ng.h/mL)
Number of subjects: 0
Study 11309549 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotrafiban (lower dose recommendation)
Number of subjects: 0
Study 11309549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9203727 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody-based IgM capture ELISA
Number of subjects: 224
Study 9203727 — intervention group
Group type: COMPARATOR
Intervention: Neutralization assay
Number of subjects: 224
Study 8498378 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure
Number of subjects: 23
Study 8498378 — intervention group
Group type: COMPARATOR
Intervention: No nasal continuous positive airway pressure
Number of subjects: 23
Study 3320366 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupenthixol 0.5 mg twice daily
Number of subjects: 55
Study 3320366 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg twice daily
Number of subjects: 55
Study 3320366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 29695262 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic H. perforatum in a potentisation of C200
Number of subjects: 100
Study 29695262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 27113931 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI + (PM or DTI)
Number of subjects: 114
Study 27113931 — intervention group
Group type: COMPARATOR
Intervention: MRI + NE
Number of subjects: 114
Study 25005834 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 IU/day
Number of subjects: 53
Study 25005834 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,000 IU/day
Number of subjects: 53
Study 25005834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 25005834 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 53
Study 23106759 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance First (8-week stability skills maintenance module followed by a 20-week behavioral weight-loss program)
Number of subjects: 267
Study 23106759 — intervention group
Group type: COMPARATOR
Intervention: Weight Loss First (20-week behavioral weight-loss program followed by an 8-week problem-solving skills maintenance module)
Number of subjects: 267
Study 23106759 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance First
Number of subjects: 267
Study 23106759 — intervention group
Group type: COMPARATOR
Intervention: Weight Loss First
Number of subjects: 267
Study 20413383 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal bone density information via dual‐energy X‐ray absorptiometry (DXA)
Number of subjects: 196
Study 20413383 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 196
Study 18854910 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) after mitoxantrone induction (20 mg/d SC)
Number of subjects: 40
Study 18854910 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) after mitoxantrone induction
Number of subjects: 40
Study 18854910 — intervention group
Group type: COMPARATOR
Intervention: Glatiramer acetate (GA) alone (20 mg/d SC)
Number of subjects: 40
Study 17081391 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal septal myocardial ablation
Number of subjects: 37
Study 17081391 — intervention group
Group type: COMPARATOR
Intervention: Subaortic ventriculotomy
Number of subjects: 37
Study 17081391 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both interventions
Number of subjects: 37
Study 12922120 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphtheria-tetanus toxoid-acellular pertussis vaccine
Number of subjects: 97
Study 12922120 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal C conjugate vaccine
Number of subjects: 97
Study 10342425 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA (eutectic mixture of 2.5% prilocaine and 2.5% lidocaine)
Number of subjects: 9
Study 10342425 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 9
Study 10342425 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose topical capsaicin (1%)
Number of subjects: 9
Study 8641230 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) at a target dosage of 800 mg/day (400 mg twice daily)
Number of subjects: 56
Study 8641230 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 56
Study 8641230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 1523351 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 + 3 chemotherapy protocol
Number of subjects: 76
Study 1523351 — intervention group
Group type: COMPARATOR
Intervention: TADOP chemotherapy protocol
Number of subjects: 76
Study 7100823 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin, 50 mg/kg twice daily
Number of subjects: 14
Study 7100823 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivampicillin, 50 mg/kg twice daily
Number of subjects: 14
Study 7100823 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular ampicillin
Number of subjects: 14
Study 31070690 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib plus HAIC (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, fluorouracil bolus 400 mg/m2 on day 1, and fluorouracil infusion 2400 mg/m2 for 46 hours, every 3 weeks)
Number of subjects: 247
Study 31070690 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib (400 mg twice daily)
Number of subjects: 247
Study 28270335 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based CBT intervention (Thinking Forward)
Number of subjects: 162
Study 28270335 — intervention group
Group type: COMPARATOR
Intervention: Primary care treatment as usual (TAU)
Number of subjects: 162
Study 26859106 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 0
Study 26859106 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0
Study 24219891 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fructose diet (150 g per day for 4 weeks)
Number of subjects: 20
Study 24219891 — intervention group
Group type: COMPARATOR
Intervention: High-glucose diet (150 g per day for 4 weeks)
Number of subjects: 20
Study 17943364 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal endoscopic microsurgery (TEM)
Number of subjects: 70
Study 17943364 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic resection (LR) via total mesorectal excision
Number of subjects: 70